Is INFI or BTI a better dividend investment in 2026?

INFI currently yields 25000.00% with a 5% 5-year dividend growth rate. BTI yields 5.40% with 5% growth. The better choice depends on your goal: INFI offers higher current income.

What is the dividend yield difference between INFI and BTI?

INFI has a forward dividend yield of 25000.00% ($2.00/share annually). BTI yields 5.40% ($3.15/share annually). The yield gap is 24994.60 percentage points.

Home › Compare › INFI vs BTI

INFI vs BTI: Dividend Comparison 2026

INFI yields 25000.00% · BTI yields 5.40%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 INFI wins by $481652020747103174656.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

INFI

● Live price

25000.00%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$481652020747103174656.00M

Annual income

$477,891,679,681,809,340,000,000,000.00

Full INFI calculator →

BTI

● Live price

5.40%

Share price

$58.26

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.8K

Annual income

$2,802.29

Full BTI calculator →

Portfolio growth — INFI vs BTI

📍 INFI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	INFI	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, INFI + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

INFI pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INFI

Annual income on $10K today (after 15% tax)

$2,125,000.00/yr

After 10yr DRIP, annual income (after tax)

$406,207,927,729,537,960,000,000,000.00/yr

BTI

Annual income on $10K today (after 15% tax)

$459.05/yr

After 10yr DRIP, annual income (after tax)

$2,381.95/yr

At 15% tax rate, INFI beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INFI + BTI for your $10,000?

INFI: 50%BTI: 50%

100% BTI50/50100% INFI

Portfolio after 10yr

$240826010373551587328.00M

Annual income

$238,945,839,840,904,670,000,000,000.00/yr

Blended yield

99.22%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

INFI

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

-63.6

Piotroski

3/9

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.3% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INFI buys

BTI buys

No recent congressional trades found for INFI or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricINFIBTI

Forward yield	25000.00% ✓	5.40%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$481652020747103174656.00M ✓	$37.8K
Annual income after 10y	$477,891,679,681,809,340,000,000,000.00 ✓	$2,802.29
Total dividends collected	$481404327977371041792.00M ✓	$14.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Hold	Buy

Year-by-year: INFI vs BTI ($10,000, DRIP)

Year	INFI Portfolio	INFI Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$2,510,700	$2,500,000.00	$11,301	$601.08	+$2.50M → INFI
2	$589,298,599	$586,612,149.53	$12,799	$706.58	+$589.29M → INFI
3	$129,309,604,119	$128,679,054,618.90	$14,527	$832.38	+$129309.59M → INFI
4	$26,527,150,102,459	$26,388,788,826,051.22	$16,527	$982.75	+$26527150.09M → INFI
5	$5,087,743,001,217,608	$5,059,358,950,607,977.00	$18,846	$1,162.95	+$5087743001.20M → INFI
6	$912,316,496,169,531,500	$906,872,611,158,228,600.00	$21,545	$1,379.49	+$912316496169.51M → INFI
7	$152,954,929,371,424,950,000	$151,978,750,720,523,570,000.00	$24,694	$1,640.41	+$152954929371424.91M → INFI
8	$23,976,822,470,935,107,000,000	$23,813,160,696,507,682,000,000.00	$28,378	$1,955.69	+$23976822470935108.00M → INFI
9	$3,514,337,444,199,857,700,000,000	$3,488,682,244,155,957,000,000,000.00	$32,702	$2,337.79	+$3514337444199857664.00M → INFI
10	$481,652,020,747,103,200,000,000,000	$477,891,679,681,809,340,000,000,000.00	$37,794	$2,802.29	+$481652020747103174656.00M → INFI

INFI vs BTI: Complete Analysis 2026

INFI — Stock

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Full INFI Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this INFI vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INFI vs SCHD INFI vs JEPI INFI vs O INFI vs KO INFI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.